Gilead Hopes To Dodge New Trial With CF Antibiotic
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s complete response finds the Cayston NDA not approvable as is.
You may also be interested in...
FDA Denies Gilead’s Appeal Of Aztreonam Lysine “Complete Response” Letter
Gilead has not yet discussed with FDA whether ongoing studies will be sufficient for resubmission of the inhaled antibiotic for use by cystic fibrosis patients.
FDA Denies Gilead’s Appeal Of Aztreonam Lysine “Complete Response” Letter
Gilead has not yet discussed with FDA whether ongoing studies will be sufficient for resubmission of the inhaled antibiotic for use by cystic fibrosis patients.
With Capital Scarce, Charities Emerge as a Stronger Force on Start-Up Scene
Disease-oriented foundations and cash-strapped biotechs are increasingly seeking common ground: as more becomes known about the mechanisms by which a given disease operates, foundation boards are finding more opportunities to fund promising start-ups and established biotechs.